Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome

Br J Dermatol. 2007 Nov;157(5):1032-6. doi: 10.1111/j.1365-2133.2007.08157.x. Epub 2007 Sep 13.

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL) observed mainly in Sudan and India where it follows treated VL in 50% and 10% of cases, respectively. We report a 46-year-old patient with acquired immune deficiency syndrome who, 7 months after diagnosis of VL, developed PKDL and uveal leishmaniasis following HAART-induced immune recovery. In southern Europe PKDL seems to be an emerging clinical presentation among human immunodeficiency virus (HIV)-infected patients experiencing HAART-induced immune recovery after a previous diagnosis of VL. The best treatment among HIV-infected patients remains to be determined.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Americas
  • Antiprotozoal Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Asia
  • Humans
  • Italy / ethnology
  • Leishmaniasis, Cutaneous / drug therapy
  • Leishmaniasis, Cutaneous / etiology*
  • Leishmaniasis, Visceral / complications*
  • Male
  • Middle Aged
  • Pentamidine / therapeutic use
  • Phosphorylcholine / analogs & derivatives
  • Phosphorylcholine / therapeutic use
  • Travel

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine
  • Pentamidine